Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 3
2013 3
2014 8
2015 7
2016 6
2017 9
2018 5
2019 11
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: dal bello mg. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Ricciuti B, et al. Among authors: dal bello mg. J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1. J Cancer Res Clin Oncol. 2019. PMID: 30506406 Clinical Trial.
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, Grossi F. Genova C, et al. Among authors: dal bello mg. J Clin Med. 2019 Oct 1;8(10):1566. doi: 10.3390/jcm8101566. J Clin Med. 2019. PMID: 31581482 Free PMC article.
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.
Coco S, Truini A, Vanni I, Dal Bello MG, Alama A, Rijavec E, Genova C, Barletta G, Sini C, Burrafato G, Biello F, Boccardo F, Grossi F. Coco S, et al. Among authors: dal bello mg. Curr Drug Targets. 2015;16(1):47-59. doi: 10.2174/1389450116666141210094640. Curr Drug Targets. 2015. PMID: 25495923
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds.
Tagliamento M, Genova C, Rossi G, Coco S, Rijavec E, Dal Bello MG, Boccardo S, Grossi F, Alama A. Tagliamento M, et al. Among authors: dal bello mg. Expert Opin Investig Drugs. 2019 Jun;28(6):513-523. doi: 10.1080/13543784.2019.1627326. Epub 2019 Jun 7. Expert Opin Investig Drugs. 2019. PMID: 31159588 Review.
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R. Ricciuti B, et al. Among authors: dal bello mg. Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27. Clin Lung Cancer. 2019. PMID: 30910574 Clinical Trial.
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P. Sarocchi M, et al. Among authors: dal bello mg. Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub 2018 Mar 22. Oncologist. 2018. PMID: 29567824 Free PMC article.
Exosomes: a new horizon in lung cancer.
Vanni I, Alama A, Grossi F, Dal Bello MG, Coco S. Vanni I, et al. Among authors: dal bello mg. Drug Discov Today. 2017 Jun;22(6):927-936. doi: 10.1016/j.drudis.2017.03.004. Epub 2017 Mar 10. Drug Discov Today. 2017. PMID: 28288782 Review.
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.
Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F. Bonaventura A, et al. Among authors: dal bello mg. Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358. doi: 10.1007/s00262-019-02367-z. Epub 2019 Jul 20. Cancer Immunol Immunother. 2019. PMID: 31327024
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
Carbone F, Grossi F, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F. Carbone F, et al. Among authors: dal bello mg. Clin Exp Metastasis. 2019 Oct;36(5):449-456. doi: 10.1007/s10585-019-09984-z. Epub 2019 Aug 2. Clin Exp Metastasis. 2019. PMID: 31376097 Clinical Trial.
56 results
Jump to page
Feedback